Navigation Links
Omeros Corporation Reports First Quarter 2013 Financial Results
Date:5/10/2013

mary safety data expected to support the initiation of OMS721 clinical studies in mid-year 2013. The pharmacokinetic results in primates demonstrated that subcutaneous administration of OMS721 resulted in maximal inhibition of the lectin pathway within six hours of administration and maintained it for two or more weeks. In addition, the bioavailability and pharmacokinetics observed in both species are expected to support subcutaneous administration in patients at a frequency of once weekly, bi-monthly or possibly at even longer intervals.
  • Announced the successful completion of the 90-day safety database lock in the second of Omeros' two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery™ product designed to maintain intraoperative mydriasis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. Omeros intends to submit a New Drug Application for OMS302 to the U.S. Food and Drug Administration this quarter and a Marketing Authorization Application to the European Medicines Agency in mid-2013.
  • Reported that its proprietary Cellular Redistribution Assay technology, which to date has successfully "unlocked" 46 of the 80 total Class A orphan G protein-coupled receptors (GPCRs) for drug development, has identified small molecules that interact with a Class B GPCR. Like the Class A GPCRs, Class B receptors are important players in a broad range of disorders, having been linked to various types of cancer (e.g., breast, brain, prostate, kidney, liver, pancreatic and gastrointestinal); multiple sclerosis, attention deficit-hyperactivity, learning and memory impairments, depression and other neuropsychiatric disorders; multiple metabolic disorders including diabetes and obesity; immunologic disorders; osteoporosis and i
    '/>"/>

  • SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
    3. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
    4. Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
    5. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
    6. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
    7. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
    8. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
    9. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
    10. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
    11. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... , and MARSEILLE, France , July ... Exclusive global license from University of Tokyo enables development ... (NGS) gene panels, for blood cancers  Mutations ... indicate favorable prognosis for patients with bone marrow disorders ... for developing companion diagnostics to guide treatment with new ...
    (Date:7/24/2014)... 2014 Amgen (NASDAQ: AMGN ) today ... on Tuesday, July 29, 2014, after the close of the ... conference call with the investment community at 2 p.m. PT. ... A. Bradway , chairman and chief executive officer, and other ... of the conference call will be simultaneously broadcast over the ...
    (Date:7/24/2014)... 2014 Many new dentists who are opening their ... that their practice will be a success. DentalDisposables.net is here ... use the most can make all the difference. Dentistry is ... discovered that purchasing discount dental supplies can make ... to successful dentists across the United States ...
    Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2Dental Supplies Online is Key to Dental Success...Really! 2
    (Date:7/24/2014)... off nighttime production of the hormone melatonin, renders breast ... cancer drug, says a new study by Tulane University ... Melatonin Disruption by Exposure to Light at Night Drives ... in the journal Cancer Research , is the ... success of tamoxifen in treating breast cancer. , , ...
    (Date:7/24/2014)... The report, “Content Delivery Networks (CDN) ... various sub-segments with an in-depth analysis and forecasting ... restraints for this market with insights on trends, ... tables and 36 figures spread through 157 pages ... Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . , Early ...
    (Date:7/24/2014)... Amy Norton HealthDay Reporter THURSDAY, ... teenage boy may be dead wrong, according to a small study ... In interviews with 33 boys between the ages of 14 and ... a girl for the closeness and trust. Very few boasted about ... a relationship with a girl. "In our culture, we have ...
    (Date:7/24/2014)... Pools and beaches are the place to be ... especially for small children, so Amica Insurance is ... the Centers for Disease Control and Prevention, children between the ... water-related injuries and deaths. It’s important to know the best ... is offering the following tips from the American Red Cross:, ...
    (Date:7/24/2014)... THURSDAY, July 24, 2014 (HealthDay News) -- Drinking caffeine ... affect roughly two-thirds of women as they go through ... are preliminary, our study suggests that limiting caffeine intake ... bothersome hot flashes and night sweats," said researcher Dr. ... the Mayo Clinic in Rochester, Minn. But caffeine ...
    Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Is Coffee Aggravating Your Hot Flashes? 2
    ... Inc. (Nasdaq and SWX: BMRN) today announced that,Jean-Jacques ... a,conference call and webcast on Tuesday, February 26, ... quarter and full year 2007 financial results., ... International Dial-in Number: 617.597.5312 Participant ...
    ... Present at Merrill Lynch,s Global Pharmaceutical Conference Feb. ... ... today that it will host a conference call and live webcast on,Wednesday, Feb. ... nine months ended Dec. 31, 2007. The Company also will provide,an operational and ...
    ... Mrs. Bojan M. Kuure, of,Jakobstad, Finland, has ... for her outstanding contributions and achievements in the,field ... About Mrs. Bojan M. Kuure, Mrs. ... a dedicated registered,nurse. She obtained a Special Registered ...
    ... Feb. 5 Watson,Pharmaceuticals, Inc. (NYSE: WPI ... the company expects to initiate shipments of,alendronate sodium ... dosage strengths when,Fosamax(R) loses market exclusivity, which is ... February 6, 2008. Alendronate sodium is the generic,version ...
    ... Feb. 5 Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical ... cancer, announced today that it will,host a conference ... Time on,Tuesday, February 19, 2008 to discuss the ... A press release will be issued before the ...
    ... Youth may be more,likely victimized while using instant messenger ... new research this week reports., The study, conducted ... Kids and Kimberly Mitchell of the University of New,Hampshire, ... youth are most likely,to experience sexual solicitation and harassment. ...
    Cached Medicine News:Health News:BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET) 2Health News:Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007 2Health News:Bojan M. Kuure Recognized by Strathmore's Who's Who Worldwide Publication 2Health News:Watson to Distribute Alendronate Tablets 2Health News:Favrille to Host Conference Call and Live Webcast to Discuss Fourth Quarter and Year End 2007 Financial Results on February 19, 2008 2Health News:Are Social Networking Sites Endangering Young Teens? Study Finds Maybe Not 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: